Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | THRA | P10827 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 4/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20158626 | 0.91 | FOLH1 (0.47) | FOLH1THRATHRBFFAR4FFAR1 | |
| SCHEMBL1404313 | 0.90 | FOLH1 (0.56) | FOLH1FFAR4FFAR1BACE1 | |
| SCHEMBL22571849 | 0.90 | FOLH1 (0.51) | FOLH1THRATHRBFFAR4FFAR1 | |
| SCHEMBL25801389 | 0.89 | FOLH1 (0.52) | FOLH1THRATHRBFFAR4GABRA1 | |
| SCHEMBL27303602 | 0.86 | FOLH1 (0.52) | FOLH1THRATHRBFFAR4FFAR1 | |
| SCHEMBL25741233 | 0.86 | FOLH1 (0.52) | FOLH1FFAR4FFAR1BACE1POLB | |
| SCHEMBL24274498 | 0.85 | FOLH1 (0.45) | FOLH1THRATHRBFFAR4 | |
| SCHEMBL18811749 | 0.85 | FOLH1 (0.58) | FOLH1THRATHRBFFAR1ALDH1A1 | |
| SCHEMBL22131080 | 0.84 | FOLH1 (0.52) | FOLH1BACE1ALDH1A1 | |
| SCHEMBL18811743 | 0.83 | FOLH1 (0.56) | FOLH1THRATHRBFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220401592-A1 | LOW MOLECULAR WEIGHT AND POLYAMIDOAMINE (PAMAM) DENDRIMER BASED PSMA-SPECIFIC DUAL CONTRAST AGENTS FOR OPTICAL AND PHOTOACOUSTIC IMAGING AND THERANOSTIC AGENTS FOR TREATING PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSTY | 2022-12-22 | — | — | US | disclosed |
| EP-3455222-B1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2022-03-02 | — | — | EP | disclosed |
| US-10857246-B2 | Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200330613-A1 | SALICYLIC ACID-BASED POLYMERIC CEST CONTRAST AGENTS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
| US-10688198-B2 | Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190192699-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2019-06-27 | — | — | US | disclosed |
| US-20180133348-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| WO-2017197251-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2016196628-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688198-B2 | Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen and uses thereof | KLK3, PSAT1, SPAG5 | FOLH1 4/4885THRA 2709/4885THRB 3531/4885 |
| US-20190192699-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | CA9, CA14, CA13 | FOLH1 15/4885THRA 1676/4885THRB 2222/4885 |
| US-20200330613-A1 | SALICYLIC ACID-BASED POLYMERIC CEST CONTRAST AGENTS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | KLK3, PSAT1, SPAG5 | FOLH1 4/4885THRA 2709/4885THRB 3531/4885 |
| US-10857246-B2 | Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof | CA9, CA14, CA13 | FOLH1 15/4885THRA 1676/4885THRB 2222/4885 |
| US-20220401592-A1 | LOW MOLECULAR WEIGHT AND POLYAMIDOAMINE (PAMAM) DENDRIMER BASED PSMA-SPECIFIC DUAL CONTRAST AGENTS FOR OPTICAL AND PHOTOACOUSTIC IMAGING AND THERANOSTIC AGENTS FOR TREATING PROSTATE CANCER | PAM, FOLH1, KLK3 | FOLH1 2/4885THRA 1139/4885THRB 2644/4885 |
| US-20180133348-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | CA9, CA14, CA13 | FOLH1 15/4885THRA 1676/4885THRB 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.